See more : Welgene Biotech Co.,Ltd. (6661.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Incannex Healthcare Limited (IXHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incannex Healthcare Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Premier Foods plc (PFODF) Income Statement Analysis – Financial Results
- Verde Resources, Inc. (VRDR) Income Statement Analysis – Financial Results
- ChinHung International, Inc. (002785.KS) Income Statement Analysis – Financial Results
- Reconnaissance Energy Africa Ltd. (RECAF) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. (CRHWF) Income Statement Analysis – Financial Results
Incannex Healthcare Limited (IXHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.incannex.com.au
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00K | 0.00 | 540.17K | 1.42M | 417.45K | 1.09K | 749.19K | 216.77K | 68.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 4.38K | 683.84K | 310.80K | 0.00 | 387.89K | 396.97K | 48.92K | 13.76K | 430.76K | 757.99K | 1.22M | 41.75K | 391.02K | 0.00 | 0.00 | 0.00 | 15.29K |
| Gross Profit | 12.00K | 0.00 | 535.79K | 739.07K | 106.65K | 1.09K | 361.30K | -180.20K | 19.38K | -13.76K | -430.76K | -757.99K | -1.22M | -41.75K | -391.02K | 0.00 | 0.00 | 0.00 | -15.29K |
| Gross Profit Ratio | 100.00% | 0.00% | 99.19% | 51.94% | 25.55% | 100.00% | 48.23% | -83.13% | 28.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.88M | 41.66M | 3.71M | 3.54M | 1.46M | 516.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.83M | 7.93M | 193.99K | 74.31K | 315.85K | 231.80K | 573.43K | 612.04K | 268.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 348.00K | 84.00K | 1.90M | 3.26M | 280.35K | 66.56K | 901.40K | 423.04K | 53.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.17M | 8.01M | 4.66M | 4.84M | 1.35M | 375.15K | 2.58M | 1.85M | 509.60K | 486.81K | 397.05K | 1.37M | 1.15M | 2.73M | 361.62K | 513.85K | 826.11K | 839.29K | 107.68K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.49K | -93.16K | -202.43K | -152.02K | -180.81K | 0.00 | -131.67K | -27.52K | -24.19K |
| Operating Expenses | 30.05M | 49.67M | 8.37M | 8.40M | 2.81M | 891.96K | 2.58M | 1.85M | 509.60K | 486.81K | 390.56K | 1.46M | 1.35M | 2.88M | 180.81K | 513.85K | 957.78K | 866.81K | 131.87K |
| Cost & Expenses | 30.05M | 49.67M | 8.38M | 9.09M | 3.12M | 891.96K | 2.97M | 2.24M | 558.53K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Interest Income | 206.00K | 244.01K | 4.55K | 2.00K | 3.05K | 1.11K | 2.36K | 6.53K | 424.25 | 3.18K | 16.34K | 122.80K | 126.22K | 99.59K | 32.62K | 6.91K | 224.50K | 44.01K | 1.18K |
| Interest Expense | 0.00 | 3.01K | 218.07 | -10.46 | -89.80 | 60.83K | 9.98K | 37.56K | 89.76 | 99.84K | 160.04K | 195.54K | 194.91K | 93.67K | 107.56K | 35.09K | 10.92K | 5.05K | 15.59K |
| Depreciation & Amortization | 103.00K | 23.00K | 7.84M | 7.64M | 28.91K | 29.95K | 42.33K | 23.27K | 11.93K | 13.76K | 36.25K | 29.41K | 42.58K | 41.75K | 45.15K | 41.29K | 41.84K | 8.56K | 340.77 |
| EBITDA | -18.50M | -13.62M | 0.00 | 0.00 | -2.59M | -861.46K | -2.22M | -2.03M | -490.22K | -2.09M | -12.10M | -13.22M | -3.27M | -4.43M | 2.38M | -2.79M | -932.05K | -820.09K | -163.01K |
| EBITDA Ratio | -154,200.00% | 0.00% | 0.00% | 0.00% | -619.34% | -79,012.56% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.04M | -49.67M | -7.84M | -7.66M | -2.70M | -890.87K | -2.22M | -2.03M | -490.22K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Operating Income Ratio | -250,341.67% | 0.00% | -1,450.78% | -538.64% | -646.62% | -81,709.63% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.61M | 857.00K | -2.45M | -863.45K | -12.42K | -110.40K | -160.17K | -14.11M | -59.59K | -1.70M | -11.48M | -11.23M | -936.03K | -1.64M | 2.80M | -2.23M | 14.81K | 41.67K | -31.78K |
| Income Before Tax | -18.43M | -48.81M | -10.29M | -8.53M | -2.71M | -1.00M | -2.38M | -16.14M | -549.82K | -2.20M | -12.30M | -13.45M | -3.51M | -4.56M | 2.23M | -2.87M | -984.81K | -833.71K | -178.94K |
| Income Before Tax Ratio | -153,575.00% | 0.00% | -1,904.94% | -599.33% | -649.59% | -91,835.01% | -317.25% | -7,444.24% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -204.00K | -229.80K | 0.00 | -88.06K | -1.32M | -1.09M | -278.89K | 0.00 | 0.00 | -18.10K | 0.00 | 0.00 | 0.00 |
| Net Income | -18.46M | -48.81M | -10.29M | -8.53M | -3.24M | -1.91M | -2.18M | -15.90M | -549.82K | -2.11M | -10.98M | -12.36M | -3.23M | -4.56M | 2.23M | -2.85M | -984.81K | -833.71K | -178.94K |
| Net Income Ratio | -153,825.00% | 0.00% | -1,904.94% | -599.33% | -776.62% | -175,041.70% | -291.24% | -7,336.20% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -1.07 | 0.90 | -1.72 | -0.73 | -1.18 | -0.37 |
| EPS Diluted | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -0.73 | 0.51 | -1.72 | -0.73 | -1.13 | -0.37 |
| Weighted Avg Shares Out | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 4.05M | 2.47M | 1.65M | 1.35M | 706.01K | 481.06K |
| Weighted Avg Shares Out (Dil) | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 5.88M | 4.37M | 1.65M | 1.35M | 738.99K | 481.06K |
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian law A newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate parent company of the group, following implementation of the Scheme of...
Top Penny Stocks To Buy? 3 To Watch Before Next Week
With the uptick of volatility in the stock market today, there's no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there's a...
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it...
Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it...
5 Cannabis Stocks You Don't Want to Hit 'Snooze' On
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference
MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr....
What Happened With These 11 Cannabis Stocks This Week?
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Incannex Healthcare rallies after airing plan to buy cannabis medicine company APIRx
Incannex Healthcare Ltd. IXHL, -4.23% shares jumped 7% after the Australia-based cannabinoid and psychedelic compound medicine development company said it would pay $93.3 million to acquire APIRx Pharmaceutical USA LLC, a pharmaceutical medicinal cannabinoid product development company.
Why Incannex Healthcare Stock Crashed Today
Profit-taking after a big gain earlier this week took its toll.
IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too
Here's what investors intrigued by today's 100% rise in Incannex Healthcare and IXHL stock may want to know about this company. The post IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports